Advertisement
Canada markets open in 4 hours 24 minutes
  • S&P/TSX

    22,468.16
    +2.79 (+0.01%)
     
  • S&P 500

    5,321.41
    +13.28 (+0.25%)
     
  • DOW

    39,872.99
    +66.22 (+0.17%)
     
  • CAD/USD

    0.7321
    -0.0015 (-0.21%)
     
  • CRUDE OIL

    77.88
    -0.78 (-0.99%)
     
  • Bitcoin CAD

    95,515.98
    -1,320.21 (-1.36%)
     
  • CMC Crypto 200

    1,475.34
    -51.08 (-3.35%)
     
  • GOLD FUTURES

    2,419.80
    -6.10 (-0.25%)
     
  • RUSSELL 2000

    2,098.36
    -4.14 (-0.20%)
     
  • 10-Yr Bond

    4.4140
    -0.0230 (-0.52%)
     
  • NASDAQ futures

    18,790.00
    -9.25 (-0.05%)
     
  • VOLATILITY

    12.05
    +0.19 (+1.60%)
     
  • FTSE

    8,392.98
    -23.47 (-0.28%)
     
  • NIKKEI 225

    38,617.10
    -329.83 (-0.85%)
     
  • CAD/EUR

    0.6745
    -0.0009 (-0.13%)
     

Exact Sciences to Participate in May Investor Conference

MADISON, Wis., May 01, 2024--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.

  • BofA Securities Health Care Conference, Las Vegas
    Fireside chat on Wednesday, May 15, 2024 at 4:40 p.m. ET

The webcast can be accessed in the investor relations section of Exact Sciences’ website at www.exactsciences.com.

About Exact Sciences Corp.

A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on X (formerly known as Twitter) @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240501269699/en/

Contacts

Nathan Harrill
Exact Sciences Corp.
investorrelations@exactsciences.com
608-535-8659